Esophageal cancer related gene-4 (Ecrg4) has been shown to be a tumor suppressor in many organs. Exosomes are naturally secreted nanosized particles that carry signal molecules including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and messenger RNAs (mRNAs) among others. Upon internalization, exosomes unload their cargos that in turn modulate the biology of the recipient cells. Mounting evidence has shown that exosomal miRNAs are functional. However, reports that exosomes carry functional mRNAs remain scarce. We found that serum exosomes contain ECRG4 open reading frame. To simulate serum exosomal ECRG4, stable cell line expressing ECRG4 was created, from which exosomes were isolated and characterized, and the internalization and the resulting biological effects of exosomal ECRG4 were evaluated. Results showed that serum exosomes contain higher levels of ECRG4 mRNA in healthy individuals than their cancer counterparts. Exosomal ECRG4 can be internalized and unload the encapsulated ECRG4 into recipient cells, which subsequently suppressed cell proliferation in vitro, and inhibited tumor growth in a xenograft mouse model. Mechanistically, ECRG4-containing exosomes, when internalized, suppressed the expression of genes commonly implicated in inflammation, cell proliferation, and angiogenesis. Given that exosome is an ideal vehicle for therapeutics delivery and that ECRG4 is a tumor suppressor gene, the exosomal ECRG4 can be exploited as a formulation for cancer gene therapy.
Introduction
Esophageal cancer related gene-4 (ECRG4, aka c2orf40) was originally cloned by messenger RNA (mRNA) differential display from normal versus cancerous epithelium of esophagus [1] . It is constitutively expressed in many tissues in quiescent state, and is down-regulated in cancers of breast, prostate, lungs, liver, colon, brain, stomach, and head and neck among other organs, and the level of Ecrg4 expression is inversely correlated with the clinocopathological staging of cancer [2] [3] [4] [5] [6] . Consistent with the down-regulation of Ecrg4 expression in tumor, restoration of Ecrg4 by forced gene expression [3, 7] , administration of soluble recombinant Ecrg4 [8] , or treatment with methyltransferase inhibitors (such as 5-Azacytidine) that inhibit promoter methylation and thus up-regulate ECRG4 gene expression [4, 9] , inhibited cell proliferation, cell migration and clonogenicity in tumor cells in vitro, and suppressed tumor growth and metastasis in several tumor cell xenograft mouse models [8, 10, 11] . These discoveries support that ECRG4 is a bona fide tumor suppressor gene and a valuable target for gene therapy.
Exosomes are nanosized membraneous particles that are selectively enriched signal molecules including proteins, lipids, microRNAs (miRNAs), long non-coding RNAs (lncRNAs), DNA, and mRNAs [12, 13] . Exosomes are secreted by almost all cells and exist in all body fluids [14] . Upon internalization, exosomes unload their cargos that in These authors contributed equally: Liang Mao, Xue Li. turn affect the biology of the recipient cells. Of all RNAs transported by exosomes, miRNA and lncRNA have been extensively studied and overwhelming articles have shown that they play critical roles in physiology and pathogenesis of many diseases [15] [16] [17] [18] . Evidence has now begun to show that mRNAs can also be encapsulated into exosomes and shuttled to recipient cells [19, 20] . However, whether these mRNAs are functional remains debatable. Valadi et al. [19] profiled RNAs from MC/9 cells, the human mast cell line HMC-1, and bone marrow mast cells, and reported the presence of mRNAs of about 1300 genes, which could be translated in in vitro translational systems [19] . However, reports from other groups showed that most exosomal mRNAs may not function through translated proteins. For example, Lasser et al. [21] reported that although exosomes of saliva, plasma, and breast milk all contain mRNAs, only serum exosomal mRNAs are polyadenylated and can be reversely transcribed using poly-dT primer. Batagov et al. [22] showed that of all exosomal mRNAs, the majority are fragments of the 3′ ends containing 3′-untranslated region (3′-UTR). These 3′-UTR-containing mRNA fragments, when internalized into recipient cells, can regulate the stability, localization, and translational activity of the same residential mRNA by competing miRNAs through a "sponge mechanism" [22] .
Exosome possesses many desirable features of an ideal drug delivery vehicle, such as biological barrier permeability, long circulating half-life, biocompatibility, minimal immunogenicity and toxicity, and the intrinsic targeting capability [14] . It has been successfully formulated to deliver various therapeutics including curcumin [23] , doxorubicin [24] , catalase [25] , and miRNA [26] . Given that ECRG4 is a tumor suppressor gene and that exosome reflects the pathophysiological state of their donor cells, we reasoned that serum exosomes contain ECRG4 mRNA, which can be exploited as a formulation for cancer gene therapy.
Results

Serum exosomes contain ECRG4 ORF
Serum exosomes from a healthy individual were prepared and total RNA was extracted and reversely transcribed. Reverse transcription-PCR (RT-PCR) showed that both an ECRG4 fragment of~200 bp (ECRG4 Frag.) and the ECRG4 open reading frame (ORF) (447 bp) can be detected (Fig. 1a) , suggesting that serum exosomes contain ECRG4 ORF. To explore whether serum exosomal ECRG4 reflects the levels of ECRG4 expression in pathophysiological states of humans, serum exosomes from nine healthy individuals and nine oral squamous cell carcinoma patients were prepared, from which total RNA was extracted and reversely transcribed, and the levels of ECRG4 were evaluated by realtime PCR. As shown in Fig. 1b, Figure S1 ).
Establishment of HEK293 stable cell line expressing full-length human Ecrg4
To simulate the higher levels of ECRG4 ORF encapsulated in serum exosomes from healthy individuals, human embryonic kidney 293 (HEK293) cells that barely express Ecrg4 were transduced with a bicistronic lentivirus expressing human full-length ECRG4 or vector control, and the stable cell lines, ECRG4-HEK293 and Vector-HEK293, were established by sorting green fluorescent protein (GFP)-positive cells using flow cytometry. Gene expression analysis showed that the expression of ECRG4 was 7.8 × 10 5 -fold higher in ECRG4-HEK293 cells than Vector-HEK293 cells (Fig. 2a) , which was validated by Western blot Fig. 1 Serum exosomes contain full-length ECRG4 mRNA. a RT-PCR shows the existence of ECRG4 as evaluated by primers amplifying both ECRG4 ORF (~450 bp) (right lane) and a fragment of ECRG4 (~200 bp) (middle lane). Lane on the left is 100 bp DNA ladder. b Real-time PCR shows that levels of exosomal ECRG4 were significantly higher in healthy humans (open triangles) than in tumor patients (open squares) (n = 9 in each group). Expression of ECRG4 was normalized to that of GAPDH, and data were presented as "mean ± SD," **p <0. 01 showing a strong 17 kDa Ecrg4-immunoreactive band in ECRG4-HEK293 cells versus non-detectable in Vector-HEK293 cells on the same blot with equal glyceraldehyde phosphate dehydrogenase (GAPDH) loading (Fig. 2b , full images were shown in Supplement Figure S2 ). When exosomes were isolated from the two stable cell lines, the expression of ECRG4 mRNA from ECRG4-HEK293 cells (ECRG4-Exo, solid bar) was 1162-fold higher than that from Vector-HEK293 (Vector-Exo, open bar) cells (Fig. 2c) . However, exosomal Ecrg4 protein was not detectable in both ECRG4-Exo and Vector-Exo, although a strong Ecrg4-immunoreactive band from ECRG4-HEK293 (ECRG4 (+)) lysate was showed up on the same blot (Fig. 2d) , suggesting limited encapsulation of Ecrg4 protein.
Characterization of ECRG4-Exo
ECRG4-Exo was chosen to be characterized by electronic microscopy, Western blot, and NanoSight3000. Consistent with reports from literatures [19] , ECRG4-Exo are spherical or cup-shaped with an average diameter around 100 nm by electron microscopy (Fig. 3a) , enriched for the well-known exosome (Exo) markers CD9 and Alix, low for endoplasmic reticulum proteins, heat-shock protein 90 kDa beta member 1 (HSP90B1, aka GRP94) and negative for Calnexin compared to total cell lysate (Lysate), by Western blot (Fig. 3b , full images were shown in Supplement Figure S3 ). NanoSight tracking analysis showed that exosomes range from 50 to 250 nm in diameter (Fig. 3c) , and with the majority being around 90 nm (Fig. 3d ).
Exosomes can be internalized into epithelial cells and unload cargo ECRG4 ORF
To demonstrate that exosomes can be internalized into epithelial cells, ECRG4-Exo was labeled with Cell Tracker TM CM-DiI (in red), which were added into TCA8113 cells, a human tongue squamous carcinoma cell line that is highly malignant and expresses negligible level of Ecrg4, which were continued to incubate for 12 h. The cells were fixed and stained with anti-α-Actin (in green), and nuclei were counterstained with 4′, 6-diamidino-2-phenylindole (DAPI) (in blue). As shown in Fig. 4 , bright red fluorence (Fig. 4b ) around blue nuclei (Fig. 4c ) in the background of green (Fig.  3a) can be seen clearly in a merged picture of TCA8113 cells (Fig. 3d) , indicating the internalization of ECRG4-Exo. The percentage of cells with internalized exosome fragments was 88.3%. Similar internalization was observed from Vector-Exo (Supplement Figure S4) . To further quantitate the internalization of exosomal ECRG4, total RNA was isolated from TCA8113 cells treated with either ECRG4-Exo or VectorExo and reversely transcribed, and real-time PCR showed that the expression of ECRG4 mRNA was almost 30-fold higher in ECRG4-Exo-treated (solid bar) than vector-Exo-treated (open bar) cells (Fig. 4e) . Unfortunately, exosomal Ecrg4 protein was not detected by Western blot (Fig. 4f ).
ECRG4-Exo inhibited cell proliferation in vitro
To further demonstrate the encapsulated ECRG4 ORF is functional, TCA8113 cells were seeded at 0.3 × 10 6 cells per well in 6-well plates for overnight. Cells were synchronized by culturing in serum-free medium for 12 h, refreshed with 2 ml complete medium containing 5 μg of either ECRG4-Exo or Vector-Exo, and continued to incubate for another 24 h. Then cells were trypsinized, washed with phosphate-buffered saline (PBS), and fixed with 70% EtOH for overnight at 4°C, spun down, washed with PBS, incubated with 500 μl PI/RNase (BD 550825), and proceeded to flow cytometry following vendor's instructions. Compared to Vector-Exo, ECRG4-Exo treatment caused cell cycle arrest at G 0 /G 1 (Vector-Exo versus ECRG4-Exo, 40.48% versus 46.39%) and G 2 phases (13.44% versus 16.12%) and a significant delayed progression from G 0 /G 1 to S phase (46.07% versus 37.49%) in TCA8113 cells (Fig. 5a, b) . This growth inhibitory effect of ECRG4-Exo was further evaluated with Cell Counting Kit-8 (CCK8). As shown in Fig. 5c , cell proliferation of TCA8113 was decreased 58% in ECRG4-Exo-treated (solid bar) relative to Vector-Exo-treated (open bar) cells. To exclude the celltype-specific growth inhibitory effect, A549 cells, an adenocarcinomic human alveolar basal epithelial cell line that also expresses low level of ECRG4, were treated at parallel with the aforementioned TCA8113 cells, compared to Vector-Exo, ECRG4-Exo treatment caused cell cycle arrest at G 0 /G 1 (Vector-Exo versus ECRG4-Exo, 54.34% versus 63.97%) and a significant delayed progression from G 0 /G 1 to S phase (29.23% versus 24.16%) and from S to G 2 phase (16.04% versus 11.83%) in A549 cells (Fig. 5d , e), which again was validated with CCK8 assay showing a 42% decreased proliferation in ECRG4-Exo-treated (solid bar) compared to Vector-Exo-treated (open bar) treated cells ( Fig. 5f ).
ECRG4-Exo inhibits the expression of genes commonly involved in inflammation, cell proliferation, and angiogenesis
To explore the potential molecular mechanisms underlying the observed growth inhibitory effect, ECRG4-Exo or Vector-Exo was incubated with TCA8113 cells, respectively, for 12 h, and the expression of genes commonly implicated in inflammation, cell proliferation, and angiogenesis were evaluated by real-time PCR. As shown in Fig. 6 , treatment with ECRG4-Exo (solid bars) significantly decreased the expression of interleukin-1b (IL1b) (Fig. 6a) , IL6 (Fig. 6b) , monocyte chemoattractant protein-1 (MCP1) (Fig. 6c) , nuclear factor-kappab (NF-kb) p50 (Fig. 6d) , vascular endothelial growth factor A (VEGFA) (Fig. 6e) , and cyclin-dependent kinase-4 (CDK4) (Fig. 6f ) compared to that in Vector-Exo-treated cells (open bars). These results suggest that the tumor suppression effect of ECRG4-Exo observed was most likely mediated by the inhibition of inflammation, cell proliferation, and angiogenesis. 
ECRG4-Exo inhibited tumor growth in vivo in TCA8113 cell xenograft mouse model
To prove the encapsulated ECRG4 mRNA is functional in vivo, a TCA8113 cell xenograft mouse model was established to evaluate the tumor-suppressive effect in vivo. Briefly, TCA8113 cells were cultured to about 80-90% confluent in 10-cm dishes. Cells were then primed with 40 µg of either ECRG4-Exo or Vector-Exo for 4 h, which were then washed with PBS, harvested, diluted with PBS to 10 7 cells/ml. One hundred microliters of the cell suspension was inoculated subcutaneously on the right shoulder area into nude mice. After that, 5 µg of either ECRG4-Exo or VectorExo was given intravenously on day 3, 6, and 9 post graft for a total of three times. Starting on day 2, body weight, food consumption, and the volume of tumors were monitored every other day until day 24, when mice were euthanized and the primary tumors were isolated, weighed, and quantitated. There were no significant differences on average body weight and food consumption between ECRG4-Exo and Vector-Exo groups (data not shown). However, the average tumor volume was significantly smaller in ECRG4-Exo than in Vector-Exo treated group on days 8, 14, 16, 20, 22, and 24 ( Fig. 7c, p <0 .05). When mice were euthanized, the sizes of primary tumors in ECRG4-Exo treated group (Fig. 7a) were grossly smaller than that of Vector-Exo-treated mice (Fig. 7b) by naked eyes. When the primary tumors were isolated and displayed under a ruler, the gross dimension of tumors from ECRG4-Exo-treated mice seemed smaller than that from VectorExo-treated mice (Fig. 7d) , and the average weight of the tumors in ECRG4-Exo group (Fig. 7e, solid bar) was significantly smaller than in Vector-Exo group (Fig. 7e , open bar) (p <0.05). When tumor tissues were paraffin-embedded and sectioned, hematoxylin and eosin (HE) staining showed that tissues from ECRG4-Exo-treated mice contained dense tumor cells with clear boundary and less extracellular components (Fig. 8b) compared to sparse tumor cells without clear-cell boundary and much more extracellular components in Vector-Exo-treated mice (Fig. 8a) under low magnification. Under high magnification, heavy lymphocyte infiltration (high-density round dots indicated by red arrows) was clearly observed in tumors from Vector-Exotreated mice (Fig. 8a, top panel) compared to sparsely infiltrated lymphocytes in tumors from ECRG4-Exo-treated mice (Fig. 8b, top panel) , suggesting the potential antiinflammatory role of exosomal ECRG4.
Discussion
In this report, we show that serum exosomes contain fulllength ECRG4 mRNA that reflects the higher level of its expression in quiescent state relative to the decreased expression in cancer. To prove the potential function of serum exosomal ECRG4 mRNA, stable cell line expressing ECRG4 was created and from which exosomes were isolated. These engineered exosomes contained higher levels of Ecrg4 mRNA that could be internalized into TCA8113 cells, leading to increased levels of 
Data were presented as "mean ± SD," **p <0.01 ECRG4 expression, which in turn inhibited the malignant phenotypes of TCA8113 cells in vitro and suppressed tumor growth and metastasis in vivo. We further demonstrated that these exosomal ECRG4 caused significantly decreased expression of genes commonly involved in inflammation, angiogenesis, and cell proliferation of recipient cells, which might have contributed to the observed tumor suppression.
Exosome is an ideal therapeutics vehicle and has been manipulated to carry a wide variety of therapeutics for cancer therapy [25, 27, 28] . Compared to the two most commonly used drug delivery systems, liposomes and polymeric nanoparticles, exosome possesses a long circulating half-life, the intrinsic ability to target tissues, biocompatibility, and minimal or no inherent toxicity issues. However, there are some issues facing exosome therapy. One is the method for exosome loading. Methods for genetic materials loading include electroporation, transient transfection, and transfection of a plasmid carrying the therapeutic gene into donor cells followed by the isolation of exosomes [14, 29] . Although the reproducibility and loading efficiency of electroporation and transient transfection vary greatly among different laboratories [30] [31] [32] [33] , the method of engineering donor cells to load exosomes seems efficient and can be easily reproduced. Using Experiments in flow cytometry were in triplicate, and in CCK8 assay were in 12 repeats, and all experiments were repeated three times. Data were presented as "mean ± SD," *p <0.05 this method, ECRG4 mRNA encapsulated in ECRG4-Exo was increased 1162-fold compared to that in Vector-Exo (Fig. 2c) , whereas Ecrg4 protein enriched in exosomes, if any, would be limited (Fig. 2d) , suggesting the selective encapsulation of ECRG4 mRNA into exosomes. Another issue facing exosome therapy is the selection of source cells. Naturally secreted exosome from humans as therapeutics is limited because of the trace amount of a given cargo encapsulated, the inefficiency of the isolation methods, the limited quantity, and ethnic issues. Most exosome therapies to date have used exosomes derived from conditioned medium of cultured mesenchymal stem cells [34] and immortalized cell lines [35] because of the ease of manipulation and scalability. However, it is well known that exosome characteristics and contents reflect the parental cells, therefore exosomes from those cell lines may contain signal molecules conferring undesired negative effects such as tumorigenecity and other side effects yet to be defined. The reasons that no such negative effects have been observed are that these exosome therapies including ours were either in vitro in cell models or short-term in vivo, with predefined endpoints such as downregulation of target gene expression in a given tissue, or suppressed growth of xenografted tumors.
ECRG4 encodes a pre-pro-peptide that can be processed tissue dependently into multiple small peptides with diverse, even opposite biological effects [10, [36] [37] [38] . Therefore, the molecular mechanisms underlying the tumorsuppressive effect of Ecrg4 must not be singular. Indeed, the anti-tumor effects of Ecrg4 has been attributed to its inhibition of the expression of NF-kb [6] , cyclins and p27 [39] , interaction with other tumor suppressors [40] , binding to its receptor [41] , and modulation of the type-I interferon Experiments were in pentaplicate and repeated three times. Expressions normalized to that of GAPDH were presented as "mean ± SD," *p <0.05 signaling pathway [11] , although the Ecrg4 peptides that are responsible for each mechanism remain to be determined. Here, exosomal ECRG4 inhibited tumor cell proliferation in vitro and tumor burden in vivo, and the molecular mechanisms may be attributed to (1) the inhibition of inflammation as evidenced by significantly decreased lymphocyte infiltration in tumor tissues from ECRG4-Exotreated (Fig. 7b) mice than that from Vector-Exo-treated mice (Fig. 7a) and by the suppressed expression of genes commonly implicated in inflammation such as NF-kb, IL1b, IL6, and MCP1 (Fig. 8); (2) the dys-regulation of cell cycle as evidenced by cell cycle arrest at G 0 /G 1 delayed progression from G 0 /G 1 to S phase (Fig. 5 ) and suppressed expression of CDK4 (Fig. 8f) ; and (3) the inhibition of angiogenesis as evidenced by inhibited gene expression of VEGFA (Fig. 8g ) that has been shown to play a critical role in tumor growth and metastasis [42] .
It is worth mentioning that unlike exosomal-miRNA gene therapy, where miRNA target mRNAs through binding to the 3′-UTR, which leads to either silence or degrade the RNA of interest thus decreasing protein expression [43] , exosomal-mRNA gene therapy must take effect through translated protein. However, attempts to detect Ecrg4 protein in recipient TCA8113 cells were not successful. One of the explanations is that Ecrg4 is a secreted protein [37, 44] , which made it less likely to be detected in the cell lysate in our experiments. If this is the case, the question that what processed Ecrg4 peptides are responsible for its tumorsuppressive effect remains open.
In summary, we have discovered that serum exosome contains full-length ECRG4 mRNA and proved the concept that genetically engineered exosomal ECRG4 can be exploited as a formulation for cancer gene therapy.
Materials and methods
Materials
HEK293 cells were originally purchased from ATCC, and TCA8113 cells and A549 were originally purchased from Shanghai Suer Biological Technology. Cells were 
Ethics approval and consent to participate
All animal studies were performed in accordance with the Chinese National Guidelines for the Use and Care of Experimental Animals. All study protocols including animal studies and usage of human peripheral blood were approved by the Ethics Committee of Southwest Medical University. Human peripheral blood samples were collected from both patients and controls upon their routine visits and an oral consent was obtained and the consent form was signed by each individual prior to the blood withdrawal.
Construction of lentivirus expressing human Ecrg4 and establishment of Ecrg4 stable cell line
Human ECRG4 ORF (GenBank: AF325503.1) was amplified by PCR with forward primer (5′-ATGACTC GAGTGCTCGCGCCCCGCCGCCATG-3′) containing an XhoI site and reverse primer (5′-TCATGGATTCTGTGGCAAGTCATGGTTAGT-3′) containing a BamHI site. PCR products were purified and cloned into the bicistronic vector, pLVX-IRES-ZsGreen1 (Clontech). The plasmid was sequenced to confirm its identity. Lentivirus was packaged using Lenti-X™ Packaging Single Shots (G glycoprotein of the vesicular stomatitis virus) (Clontech) as instructed by the vendor. HEK293 cells were transduced with ECRG4-lentivirus or controllentivirus for 48 h and stable cells were selected twice by FACS gating for GFP-positive cells. The GFP-positive cells, designated as ECRG4-HEK293 and Vector-HEK293 respectively, were propagated and maintained for exosome isolation. The expression of Ecrg4 was confirmed by both real-time PCR and Western blot as described below [34] .
Exosome isolation and characterization
Exosomes were isolated using ultracentrifugation method. For serum exosome isolation, 2 ml of whole blood was withdrawn from nine patients with oral squamous cell carcinoma and nine healthy individuals, and serum was prepared from each. Serum diluted with equal volume of cold PBS was spun at 2000 × g for 30 min at 4°C. The supernatant was spun at 110,000 × g for 2 h at 4°C. The pellet was dissolved into 2 ml cold PBS, filtered through 0.22 μm filter, and spun again at 110,000 × g for 70 min. The pellet was then dissolved into 200 μl cold PBS and stored at −80°C for further analysis. For exosomes from conditioned medium, 48 h before medium collection, stable cell lines were washed with PBS once and refreshed with RPMI1640 supplemented with 5% exosome-depleted fetal bovine serum. The protocol was the same as that for serum exosomes except that the exosome pellets from the first ultracentrifugation were dissolved into TE (containing RNase at the final concentration of 1 mg/ml) at one-tenth of the original volume of the conditioned medium (Tris-EDTA, pH = 8.0), and continue to incubate at room temperature for 30 min to remove any RNAs outside exosomes, which were then spun down at 110,000 g for another 70 min, re-dissolved into cold PBS at one-tenth of the original volume of the conditioned medium, and stored at −80°C for downstream experiments. The morphology of exosomes were observed under electron microscopy using negative staining, the size and distribution were analyzed by NanoSight300, and the authenticity was confirmed by Western blot using exosome-specific markers CD63 and CD9 and exosome negative endoplasmic reticulum markers calnexin and GRP94. Exosomes were quantified by total protein concentration using BCA method.
For the successful packaging of ECRG4 mRNA, exosomes from ECRG4-HEK293 or Vector-HEK293 cells, designated as ECRG4-Exo and Vector-Exo, respectively, were prepared as described above. RNA was prepared using Trizol method as instructed by the vendor. A total of 500 ng of RNA was reversely transcribed in a 20 μl reaction, and 1 μl was used for real-time PCR to analyze the relative expression of ECRG4 using GAPDH as internal control as described below.
Internalization of exosomes into TCA8113 cells
Exosomes were labeled by incubating with Cell Tracker TM CM-DiI (Thermo, C7000) at the final concentration of 1 μg/ ml at 37°C for 30 min, followed by 4°C for 15 min. Exosomes were washed twice with PBS and spun down at 4°C, 120,000 × g for 90 min. The labeled exosomes were dissolved into PBS and stored at −80°C for the downstream experiments. For exosome internalization, TCA8113 cells were seeded into a 6-well plate with coverslips at 0. 3 × 10 6 per well the day before the experiment. The labeled exosomes were added into the cells and continued to incubate for 12 h. The cells were then fixed and proceeded for immunofluorence with anti-Actin antibody and nuclei counter-staining. The images were acquired under confocal microscopy.
Flow cytometry analysis of cell cycle TCA8113 or A549 cells were seeded in 6-well plate at 0.3 × 10 6 /well the day before the experiments. Cells were refreshed with serum-free medium for 12 h and then with complete medium containing 20 μg of either ECRG4-Exo or Vector-Exo, and continued to incubate for another 24 h. Cells were then washed with ice-cold PBS, harvested, and fixed in 70% ethanol for 30 min. Cells were treated with RNase A and stained with 25 μg/ml propidium iodide (PI). Samples were analyzed using a FACScan flow cytometer (Becton Dickinson), according to the manufacturer's protocol.
Cell proliferation assay by CCK8
TCA8113 or A549 cells were seeded into a 96-well plate with 2000 cells/well. After 24 h, cells were refreshed with complete medium containing 100 ng of either ECRG4-Exo or Vector-Exo per well and continued to incubate for 48 h. Eight microliters of CCK8 solution was added to each well and continued to incubate for 1 h at 37°C. The optical density was determined at an absorbance of 450 nm using a microplate reader (Synergy2, BioTek). Each treatment includes 12 wells in each group and the experiments were repeated at least three times.
Western blot
Western blot was performed using the protocol described previously. Briefly, cells or exosomes were lysed with RIPA buffer, sonicated, boiled for 10 min, and spun down. The supernatants were quantitated using the BCA assay. Ten micrograms of each lysate was resolved on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to polyvinylidene fluoride membrane, and incubated sequentially with primary and secondary antibodies. In detecting Ecrg4, a positive lysate from ECRG4-HEK293 stable cell line was always loaded side by side with unknown samples.
RNA preparation, RT-PCR, and real-time quantitative PCR
For analysis of serum exosomal ECRG4, total RNA was extracted from 5 µg of exosomes of each subject and 0.5 µg of RNA was reversely transcribed in a 20 µl reaction. Of the 20 µl cDNA, 1 µl was used for RT-PCR. The PCR conditions were 95°C for 5 min, 30 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s, followed by 72°C for 1 min, and a final hold at 4°C. Ten microliters of PCR products were analyzed on 1% agarose gel. Primers for amplifying 200 bp ECRG4 fragment were sense (5′-ACTAAGA CTAAAGTGGCCGTTG-3′) and anti-sense (5′-CATAG TATTCATGTCCAT-3′), and for ECRG4 ORF were sense (5′-ATGGCTGCCTCCCCCGCGCG-3′) and antisense (5′-TCAATCGTAGTTGACGCTG-3′). For ECRG4 expression from ECRG4-Exo treated cells, TCA8113 cells were seeded in a 12-well plate the day before the experiments. Cells were treated with 5 µg of ECRG4-Exo or Vector-Exo for 24 h. Total RNA was prepared using RNeasy kit (Qiagen). One microgram of total RNA was reversely transcribed in a total volume of 20 µl with RevertAid M-MuLV RT (Thermo 1622) following the manufacturer's instructions. Of the 20 µl cDNA, 1 µl was used in a 25 µl reaction for real-time PCR using SYBR Green Real Time PCR Mix (Qiagen). The PCR conditions were 95°C for 2 min, followed by 40 cycles of 95°C for 20 s and 60°C for 10 s. The PCR efficiency for each primer pair was >95%. Primers used were ECRG4 (For. 5′-ACT AAGACTAAAGTGGCCGTTG-3′ and Rev. 5′-AATT TCGCTTCGTCAAAGCCC-3′), NF-kb p50 (For. 5′-AA CAGAGAGGATTTCGTTTCCG-3′ and Rev. 5′-TTTG ACCTGAGGGTAAGACTTCT-3′), IL1β (For. 5′-ATG ATGGCTTATTACAGTGGCAA-3′ and Rev. 5′-GTCG GAGATTCGTAGCTGGA-3′), IL6 (For. 5′-ACTCACCTC TTCAGAACGAATTG-3′ and Rev. 5′-CCATCTTTGGA AGGTTCAGGTTG-3′), MCP1 (For. 5′-CAGCCAGATGC AATCAATGCC-3′ and Rev. 5′-TGGAATCCTGAACC CACTTCT-3′), VEGFA (For. 5′-AGGGCAGAATCATCA CGAAGT-3′ and Rev. 5′-AGGGTCTCGATTGGATGG CA-3′), CDK4 (For. 5′-ATGGCTACCTCTCGATATGA GC-3′ and Rev. 5′-CATTGGGGACTCTCACACTCT-3′), and GAPDH (For. 5′-GAGTCCACTGGCGTCTTCA-3′ and Rev. 5′-TCTTGAGGCTGTTGTCATACTTC-3′).
Establishment of TCA8113 cell xenograft mouse model and exosome treatment TCA8113 cells were propagated, washed with PBS, and harvested in a final density of 10 6 cells/ml. A total of 12 nude mice (Balb/c, 5-6 weeks, either sex) (Beijing HFK Bioscience Company) were divided equally into experimental and control groups (n = 6), and one million cells were subcutaneously injected at the shoulder area. Before injection, cells in a 10-cm dish were primed with 40 µg of either ECRG4-Exo or Vector-Exo for 4 h, which were then washed, harvested, and diluted with PBS to 10 7 cells/ml. One hundred microliters of the cell suspension was inoculated subcutaneously on the right shoulder area into nude mice. Five micrograms of either ECRG4-Exo or Vector-Exo was given intravenously on days 3, 6, and 9 post graft for a total of three times. Mice were maintained under sterile condition with free access to food and water. The body weight, food consumption, and the volume of the primary tumor were monitored every other day starting on day 2 post graft. The tumor volume (V) was calculated using formula: V = (L x S 2 )/2, where "L" is the longest diameter and "S" is the shortest diameter [45] . Mice were euthanized on day 24 and tumors were isolated and weighed.
H&E staining and assessment of inflammation
Paraffinized sections (0.6 μm) from tumors of mice treated with either ECRG4-Exo or Vector-Exo (3-10 sections/ tissue block) were stained with Gill's hematoxylin V and 1% eosin alcohol solution (H&E). The inflammation was assessed by the infiltration of lymphocytes.
Statistical analysis
Data presented as "mean ± SD" were analyzed using oneway analysis of variance with SPSS19.0, with double asterisks representing p <0.01 and asterisk representing p <0.05. All experiments were at least in triplicate and repeated three times.
